Colgate Palmolive
Trial Pipeline
Clinical Study to Assess the Efficacy of New Toothpaste Containing SnF as Compared to Colgate Cavity Protection Toothpaste on the Reduction of Enamel Erosion
NCT07442136
Efficacy of a Stannous Fluoride Toothpaste, Cetylpyridinium Chloride Mouthwash, and Battery Toothbrush Regimen in Reducing Established Dental Plaque and Gingivitis.
NCT07398846
To Validate Changes in Knowledge, Attitudes and Practices (KAPs) Related to the Know Your OQ Initiative and to Understand the Readability, Comprehension and Ease of Use of the Know Your OQ Quiz
NCT06880458
Clinical Research Study to Assess the Efficacy of Two Brushing Regimens in the Reduction of Established Dental Plaque and Gingivitis.
NCT06244303
A Clinical Trial to Assess the Safety and the Anti-caries Efficacy of COL 101 (Arginine) Non-fluoride Dentifrices in Comparison With 0.24% Sodium Fluoride (1100 Ppm F) Dentifrice Control in 10 to 14-year-old Children
NCT04750902
Gingivitis Reduction After Use of 0.45% Stannous Fluoride Toothpaste
NCT06300866
Clinical Investigation of a Toothpaste Containing Stannous Fluoride as Compared to Colgate Fluoride Toothpaste
NCT04033575
Clinical Efficacy of 10% Arginine Bicarbonate Prophylaxis Paste
NCT01072188
Clinical Study to Evaluate the Treatment of Gingivitis of Two Toothpastes
NCT00762515
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 6 |
| Phase 4 | 1 |
Therapeutic Areas
What the Pipeline for Colgate Palmolive Shows
According to the ClinicalTrials.gov registry, Colgate Palmolive is linked to 9 US clinical trials across every stage of research activity. Of those, 2 studies are currently recruiting — about 22% of the sponsor's indexed portfolio — and 6 are already marked complete, representing roughly 67% of the total. Recruiting share is one of the more practical signals here: it reflects how much of a sponsor's research is presently open to new participants, while the completed share indicates the depth of finished work that has already contributed registry results. Both counts come directly from the public ClinicalTrials.gov dataset and are refreshed on the registry side; this page mirrors the latest data pull without altering it.
The phase mix for Colgate Palmolive reports 7 late-stage studies (Phase 3 and Phase 4 combined) and 1 earlier-phase studies (Phase 1 and Phase 2). A portfolio weighted toward Phase 3 usually reflects an organization advancing candidates toward regulatory review, where the research centers on comparative efficacy and broader safety across larger populations. A heavier Phase 1 and Phase 2 tilt generally indicates exploratory work — safety, dosing, and early signal detection — and is common among research-forward sponsors that seed many early programs. Phase 4 entries, when present, track interventions already in real-world use and typically focus on long-term safety, effectiveness across subgroups, or formulation comparisons.
The top therapeutic focus area indexed for Colgate Palmolive is Gingivitis with 3 linked trials, and 7 other condition areas appear in the top list above. That distribution is a quick read of where the organization concentrates its research attention; it does not imply product availability, market share, or any clinical endorsement. All numbers on this page come from ClinicalTrials.gov maintained by the National Library of Medicine, and counts can shift as new studies are registered or existing ones update their status. This information is provided for reference and educational purposes only, not as medical, investment, or regulatory advice — verify current details directly with ClinicalTrials.gov before relying on any figure here.
Read our methodology — how this data is sourced, computed, and verified.